Exploring treatment with Ribociclib alone or in sequence/combination with Everolimus in ER+HER2−Rb wild-type and knock-down in breast cancer cell lines

Exploring treatment with Ribociclib alone or in sequence/combination with Everolimus in ER+HER2−Rb wild-type and knock-down in breast cancer cell lines

Abstract Background Breast cancer (BC) is the second most common type of cancer worldwide. Among targeted therapies for Hormone Receptor-positive (HR+) and Human Epidermal growth factor Receptor 2-negative (HER2−) BC, the Cyclin-Dependent Kinases (CDK4/6) are targeted by inhibitors such as Ribocicli...

Full description

Bibliographic Details
Main Authors: Oliviero Marinelli, Emanuela Romagnoli, Federica Maggi, Massimo Nabissi, Consuelo Amantini, Maria Beatrice Morelli, Matteo Santoni, Nicola Battelli, Giorgio Santoni
Format: Article
Language:English
Published: BMC 2020-11-01
Series:BMC Cancer
Subjects:
Breast cancer
ER + HER2-
CDK4/6 inhibitor
Ribociclib
Everolimus
Rb
Online Access:http://link.springer.com/article/10.1186/s12885-020-07619-1

Internet

http://link.springer.com/article/10.1186/s12885-020-07619-1

Similar Items